We aim to enable exceptional scientific outcomes by commercializing transformative products for researchers to unlock deep, unbiased biological information. Our initial product, the Proteograph Product Suite (Proteograph), will leverage our proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.  Proteins are the functional units of all forms of […]

  We are a leading education technology company in China with an “in-school + after-school” integrated model. Our smart in-school classroom solution delivers data-driven teaching, learning and assessment products to teachers, students and parents across over 70,000 K-12 schools, with the number of average MAUs of our products exceeding that of the next four top […]

We intend to focus on the industries that complement our management team’s background, and to capitalize on their demonstrated ability to identify and acquire businesses focusing on Health and Wellness (“H&W”) and related industries in the United States.  (Note: This SPAC IPO  was upsized at pricing – to 25 million units, from 22.5 million in […]

  We intend to focus our efforts on identifying a prospective target business with either all or a substantial portion of its activities in North America and/or Europe. We expect to focus on consumer technology and related technology businesses that have attractive growth-oriented characteristics and strong underlying demand drivers. As we focus our efforts in […]

Affirm offers a “Buy Now, Pay Later” service as an alternative to traditional credit cards. Our business benefits from broader trends in technology, retail, finance and e-commerce. For example, Gen Z and Millennials, people born between 1981 and 2012, now comprise the largest proportion of the U.S. population and are driving the rapid growth in […]

While we may pursue an acquisition opportunity in any business industry or sector, we intend to capitalize on the ability of our management team to identify, acquire and accelerate a business in the high growth sectors of TMT. This includes, but is not limited to, opportunities in interactive entertainment and games, real money gaming, digital […]

We are a revenue stage medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). We offer novel and proprietary alternatives for treating mild-to-moderate OSA as well as certain […]

We accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. Biosimulation is a powerful technology used to conduct virtual trials using virtual patients to better understand how drugs behave in different individuals. Biopharmaceutical companies use our proprietary biosimulation software throughout drug discovery and development to inform critical decisions […]

We are leading a revolution in measurement devices for chemical and biochemical analysis. We are democratizing laboratory mass spectrometry instruments with our simple handheld and desktop devices, addressing critical-to-life applications. We are reimagining where Mass Spec technology can be used if it is sufficiently small in size, low in cost, and simple to operate. We […]

While we may pursue an acquisition opportunity in any financial technology business in any geographical location, we intend to focus our search on a target that aligns with the background and experience of Motive in financial technology. We expect to focus primarily on companies that serve five primary sub-sectors of our market segment: Banking & […]